Composition for preventing and / or improving physical frailty, composition for maintaining and / or increasing muscle mass, composition for maintaining and / or improving muscle strength, composition for alleviating fatigue, composition for maintaining body weight, and composition for improving basal metabolism
Thymoquinone and/or thymohydroquinone compositions address physical frailty by promoting IGF-1 gene expression and mitochondrial activation, enhancing muscle mass, strength, and metabolic function, thereby improving overall health and longevity.
Patent Information
- Application Number
- JP2024070888
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-26
- Filing Date
- 2024-04-24
- Publication Date
- 2024-11-08
AI Technical Summary
There is a lack of effective ingredients to address physical frailty, muscle strength decline, muscle mass reduction, and metabolic decline associated with aging, and existing agents like agarooligosaccharide are insufficient.
Compositions containing thymoquinone and/or thymohydroquinone are developed to promote IGF-1 gene expression, activate mitochondria, and improve grip strength, thereby preventing and improving physical frailty, maintaining muscle mass and strength, and enhancing basal metabolism.
Thymoquinone and/or thymohydroquinone compositions effectively maintain muscle mass and strength, reduce fatigue, support body weight, and improve metabolic function, extending healthy lifespan.
Smart Images

Figure 2024159636000011 
Figure 2024159636000012 
Figure 2024159636000013
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition for preventing and / or improving physical frailty, a composition for maintaining and / or increasing muscle mass, a composition for maintaining and / or improving muscle strength, a composition for anti-fatigue, a composition for maintaining body weight, and a composition for improving basal metabolism, each of which contains thymoquinone and / or thymohydroquinone. [Background technology]
[0002] As we age, various effects occur on the body, such as decreased muscle strength and presbyopia. In particular, symptoms such as weight loss, fatigue, decreased walking speed, decreased grip strength, and decreased physical activity due to aging are called frailty. Furthermore, the decline in oral function due to aging is called oral frailty, and the decline in visual function is called eye frailty.
[0003] It is also known that frailty can be restored to a healthy state by taking measures. For example, a frailty prevention agent containing agarooligosaccharide as an active ingredient is known (Patent Document 1). However, there are still few ingredients that are effective against frailty, and new developments are needed. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] Patent No. 7236712 Summary of the Invention [Problem to be solved by the invention]
[0005] Therefore, the present inventors conducted various investigations with the objective of discovering a composition that prevents and / or improves physical frailty. [Means for solving the problem]
[0006] As a result, the present inventors discovered that thymoquinone and / or thymohydroquinone have excellent effects in preventing and / or improving physical frailty, and thus completed the present invention.
[0007] That is, the present invention is as follows. <1> A composition for preventing and / or improving physical frailty, comprising thymoquinone and / or thymohydroquinone. <2> A composition for maintaining and / or increasing muscle mass, comprising thymoquinone and / or thymohydroquinone. <3> A composition for maintaining and / or improving muscle strength, comprising thymoquinone and / or thymohydroquinone. <4> An anti-fatigue composition comprising thymoquinone and / or thymohydroquinone. <5> A composition for maintaining weight, comprising thymoquinone and / or thymohydroquinone. <6> A composition for improving basal metabolism, comprising thymoquinone and / or thymohydroquinone. <7> A composition for extending healthy lifespan, comprising thymoquinone and / or thymohydroquinone. Effect of the Invention
[0008] According to the present invention, by containing thymoquinone and / or thymohydroquinone, it is possible to provide a composition for preventing and / or improving physical frailty, a composition for maintaining and / or increasing muscle mass, a composition for maintaining and / or improving muscle strength, an anti-fatigue composition, a composition for maintaining weight, and a composition for improving basal metabolism, as the effects of promoting IGF-1 gene expression, activating mitochondria, improving grip strength, and / or maintaining body weight are achieved. [Brief description of the drawings]
[0009] [Figure 1] The measurement results (relative values) of the expression level of the IGF-1 gene are shown. [Diagram 2] The results of measuring the amount of activated mitochondria (relative values) are shown. [Diagram 3]1 shows the measurement results of mouse grip strength. [Figure 4] The results of measurement of mouse body weight (changes) are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] The composition of the present invention will be described in detail below. In this specification, the composition of the present invention is a concept that includes all of compositions for preventing and / or improving physical frailty, compositions for maintaining and / or increasing muscle mass, compositions for maintaining and / or improving muscle strength, compositions for anti-fatigue, compositions for maintaining body weight, and compositions for improving basal metabolism. In addition, the present invention is not limited to the embodiments shown below, and can be modified within the scope that a person skilled in the art can conceive of, such as other embodiments, additions, modifications, and deletions, and any embodiment is within the scope of the present invention as long as it exhibits the action and effect of the present invention.
[0011] <Thymoquinone and / or thymohydroquinone> The composition of the present invention is characterized by containing thymoquinone and / or thymohydroquinone. Thymoquinone is a derivative of 1,4-benzoquinone, an organic compound in which an isopropyl group is bonded to the 2nd position of a six-membered ring and a methyl group is bonded to the 5th position, and is also called 2-isopropyl-5-methyl-1,4-benzoquinone. Thymohydroquinone is a compound in which the oxygens at the 1st and 4th positions of thymoquinone are reduced, and is also called 2-isopropyl-5-methyl-1,4-benzenediol. Both thymoquinone and thymohydroquinone are known to exhibit dose-dependent anticancer effects, and it is expected that thymoquinone and thymohydroquinone have a common effect.
[0012] The thymoquinone and / or thymohydroquinone used in the present invention is not particularly limited as long as it is commonly used in the field of food and beverages, and can be, for example, an extract of a plant rich in thymoquinone and / or thymohydroquinone, a purified product from a plant, or a chemically synthesized product such as a reagent. Examples of plants rich in thymoquinone and / or thymohydroquinone include black cumin, Japanese laurel, Scutellaria baicalensis, horsemint, thyme, oregano, winter savory, Euonymus monarda, Euonymus arvensis, marigold, valeriana, monarda, and Ayapana. Examples of parts of plants that can be used include crushed products, extracts, pressed oils, essential oils, or purified products thereof from stems and leaves, flowers, seeds, or whole plants. The extraction method, extraction conditions, and purification method of thymoquinone and / or thymohydroquinone are not particularly limited, and known methods can be used. For example, methods for obtaining extracts, pressed oils, and essential oils include, for example, extraction with various solvents, supercritical carbon dioxide extraction, water distillation, steam distillation, microwave extraction, and pressing (cold press), and these methods may be appropriately combined. The solvent used for extraction may be either a polar solvent or a non-polar solvent, and water, methanol, ethanol, acetone, ethyl acetate, diethyl ether, n-hexane, and mixtures thereof may be used, but more preferably methanol, hydrous methanol, ethanol, hydrous ethanol, acetone, and ethyl acetate are used. In addition, acidic solvents obtained by adding organic and inorganic acids to the above-mentioned extraction solvents, and basic solvents obtained by adding organic and inorganic bases to the above-mentioned extraction solvents may also be used. In addition, the extracts, pressed oils, and essential oils may be powdered by removing the solvent or adding an excipient.
[0013] The content of thymoquinone and / or thymohydroquinone in the composition of the present invention is not particularly limited, and for example, in the solid content, it is preferably 0.005% by mass or more, more preferably 0.1% by mass or more, and from the viewpoint of preventing and / or improving physical frailty, maintaining and / or increasing muscle mass, maintaining and / or improving muscle strength, anti-fatigue effect, maintaining body weight, and improving basal metabolism, it is particularly preferably 0.2% by mass or more. There is also no particular limit to the upper limit, but it is preferably 10% by mass or less, more preferably 9% by mass or less, and particularly preferably 8% by mass or less. The content of thymoquinone and / or thymohydroquinone refers to the total amount when both thymoquinone and thymohydroquinone are contained.
[0014] The content of thymoquinone and / or thymohydroquinone in the composition of the present invention can be quantified, for example, by high performance liquid chromatography (HPLC).
[0015] <Other ingredients> In addition to the above-mentioned components, the composition of the present invention can contain other components as necessary. Examples of other components include excipients, lubricants, dietary fibers such as soluble dietary fibers and insoluble dietary fibers, proteins, various vitamins and minerals, microorganisms such as algae and yeasts, etc. Furthermore, as necessary, sweeteners, acidulants, nutritional supplements, stabilizers, binders, gloss agents, thickeners, colorants, diluents, emulsifiers, food additives, seasonings, etc., which are usually used in the food industry, can be mentioned. The content of these other components can be appropriately selected according to the form of the composition of the present invention, etc.
[0016] <Composition for preventing and / or improving physical frailty, composition for maintaining and / or increasing muscle mass, composition for maintaining and / or improving muscle strength, composition for anti-fatigue, composition for maintaining body weight, composition for improving basal metabolism> The composition of the present invention has the effects of promoting IGF-1 gene expression, activating mitochondria, improving grip strength and / or maintaining body weight, and therefore can exhibit excellent effects as a composition for preventing and / or improving physical frailty, a composition for maintaining and / or increasing muscle mass, a composition for maintaining and / or improving muscle strength, an anti-fatigue composition, a composition for maintaining body weight, and a composition for improving basal metabolism.
[0017] Specific examples of the preventive and / or improving effect on physical frailty include maintaining muscle mass that decreases with age, maintaining muscle strength and muscle endurance that decrease with age, maintaining leg muscle strength that decreases with age and improving walking ability, maintaining thigh muscle strength that decreases with age and improving walking pitch and walking speed, promoting muscle hypertrophy (muscle protein synthesis) and maintaining muscle mass, muscle strength, and muscle endurance that decrease with age, inhibiting the decomposition of muscle proteins and amino acids and maintaining muscle mass, muscle strength, and muscle endurance that decrease with age, maintaining grip strength by maintaining arm muscle strength that decreases with age, reducing temporary physical fatigue in the daily life of middle-aged and elderly people, maintaining body weight that decreases with age, supporting the improvement of basal metabolism that decreases with age, and extending healthy lifespan. Specific examples of the muscle mass maintaining and / or increasing effect include maintaining muscle mass, increasing muscle mass, and inhibiting the decrease in muscle mass. Examples of the muscle strength maintaining and / or improving effect include maintaining muscle strength, improving muscle strength, suppressing the decline of muscle strength, maintaining muscle endurance, improving muscle endurance, suppressing the decline of muscle endurance, etc. Examples of the anti-fatigue effect include reducing fatigue, making it difficult to get tired, etc. Examples of the weight maintaining effect include maintaining a declining weight. Examples of the basal metabolism improving effect include improving basal metabolism, supporting the improvement of basal metabolism, suppressing the decline of basal metabolism, etc.
[0018] The composition of the present invention has the following effects, for example: "maintaining muscle mass which declines with age", "maintaining muscle strength and muscle endurance which decline with age", "maintaining leg muscle strength which declines with age and improving walking ability", "maintaining thigh muscle strength which declines with age and improving walking pitch and walking speed", "promoting muscle hypertrophy (muscle protein synthesis) and maintaining muscle mass, muscle strength and muscle endurance which decline with age", "suppressing the breakdown of muscle proteins and amino acids and maintaining muscle mass, muscle strength and muscle endurance which decline with age", "maintaining grip strength by maintaining arm muscle strength which declines with age", "relieving temporary physical fatigue in the daily lives of middle-aged and elderly people and maintaining body weight which declines with age ... strength which declines with age", "reducing "supports the improvement of basal metabolism which declines with aging", "extends healthy life expectancy", "maintains oral function which declines with aging", "maintains visual function which declines with aging", "maintains muscle mass", "increases muscle mass", "inhibits the decline in muscle mass", "maintains muscle strength", "improves muscle strength", "inhibits the decline in muscle strength", "maintains muscular endurance", "improves muscular endurance", "inhibits the decline in muscular endurance", "relieves fatigue", "makes the body less susceptible to fatigue", "maintains a decline in body weight", "improves basal metabolism", "supports the improvement of basal metabolism", "inhibits the decline in basal metabolism" and the like are acceptable for advertising and promotion, and such advertising and promotion can be deemed to be the implementation of the present invention.
[0019] The composition of the present invention is not particularly limited as long as it is in a form suitable for oral use, but from the viewpoint of ease of ingestion, it may be in a fluid form such as a liquid, syrup, paste, gel, jelly, cream, emulsion, spray, mousse, lotion, etc. Examples of solid forms include powder, granules, tablets, chewable tablets, capsules, soft capsules, etc.
[0020] The daily usage amount of the composition of the present invention is not particularly limited, and can be appropriately set depending on the mode of use, the content of use by the user, etc. For example, the daily usage amount of the composition of the present invention is preferably 0.001 to 1000 mg / kg, more preferably 0.01 to 200 mg / kg, in terms of solid content, based on the body weight of the user, and further preferably 0.1 to 100 mg / kg from the viewpoint of exerting the effects of the composition of the present invention.
[0021] Similarly, the amount of the composition of the present invention used per time is not particularly limited. For example, the amount of the composition of the present invention used per time is preferably 0.0001 to 1000 mg / kg, more preferably 0.001 to 200 mg / kg, and further preferably 0.01 to 100 mg / kg, calculated as solid content based on the weight of the user, from the viewpoint of exerting the effect of the composition of the present invention.
[0022] Furthermore, the amount of the composition of the present invention to be used per day is not particularly limited, and may be, for example, preferably 0.1 to 50,000 mg, more preferably 1 to 10,000 mg, and from the viewpoint of exerting the effects of the composition of the present invention, particularly preferably 10 to 5,000 mg, calculated as solid content.
[0023] The amount of the composition of the present invention to be used at one time is not particularly limited, and may be, for example, preferably 0.01 to 50,000 mg, more preferably 0.1 to 10,000 mg, and from the viewpoint of exerting the effects of the composition of the present invention, particularly preferably 1 to 5,000 mg, calculated as solid content.
[0024] The packaging form of the composition of the present invention is not particularly limited and can be appropriately selected depending on the dosage form, etc., and examples thereof include blister packs such as PTPs; strip packaging; heat seals; aluminum pouches; film packaging using plastics, synthetic resins, etc.; glass containers such as vials; and plastic containers such as ampoules. EXAMPLES
[0025] The present invention will be described below based on examples. However, the present invention is not limited to these examples and can take various forms.
[0026] 1. Evaluation of IGF-1 gene expression level Insulin-like growth factor-1 (IGF-1) is an important growth factor that controls both anabolic and catabolic pathways in skeletal muscle, and IGF-1 is known to increase skeletal muscle protein synthesis via the PI3K / Akt / mTOR and PI3K / Akt / GSK3β pathways. Therefore, by confirming the promoting effect of IGF-1 gene expression, it is possible to maintain muscle mass and / or improve muscle mass by promoting the synthesis of skeletal muscle proteins. It is possible to confirm the prevention and / or improvement effect of physical frailty by increasing muscle mass and maintaining muscle mass. [Test substance] The following substances were used as test substances. A commercially available powdered extract containing thymoquinone was used. Resveratrol: A commercially available product was used as a positive control.
[0027] [Preparation of test substance] Each test substance was prepared as follows. Each test substance was dissolved in DMSO and diluted with differentiation-inducing medium so that the DMSO concentration was 0.5%. 2% HS (horse serum)-DMEM was used as the differentiation-inducing medium. The contents of the test substances used in the following tests are shown in Table 1.
[0028] [Table 1]
[0029] [Measurement of IGF-1 gene expression level] (1) Mouse myoblast cells (C2C12) were plated on a collagen-coated 24-well plate at 5.0 × 10 4 The cells were seeded at 200 cells / well and cultured for 24 hours in a 5% CO2 incubator at 37°C. (2) After removing the medium, the cells were washed twice with DMEM, and then 1 mL / well of differentiation-inducing medium (2% HS-DMEM) was added and cultured for 7 days in a 37°C, 5% CO2 incubator (to induce differentiation into myotubes). The medium was replaced every 2 to 3 days. (3) After 7 days of culture, the medium was removed and 500 μL / well of differentiation-inducing medium containing the test substance was added. (4) After 1 hour of culture in a 37°C, 5% CO2 incubator, 50 μL / well of differentiation-inducing medium containing dexamethasone was added (final dexamethasone concentration: 50 μM). Dexamethasone was dissolved in DMSO and diluted with differentiation-inducing medium so that the DMSO concentration was 0.5%. (5) After culturing for 24 hours in a 37°C, 5% CO2 incubator, RNA was extracted using an RNeasy Mini Kit (QIAGEN). (6) The obtained RNA was subjected to One Step TB Green® PrimeScript PCR. TM Real-time PCR was performed using RT-PCR Kit II (Perfect Real Time) (TaKaRa), and the gene expression level of IGF-1 was measured using IGF-1 primers (Eurofins Genomics). As an endogenous control, the gene expression level of Rn18S was measured using Rn18S primers (QIAGEN). The gene expression level of IGF-1 was calculated relative to the control value without the addition of the test substance, which was set at 1. The results are shown in Figure 1.
[0030] 1, it can be seen that Example 1 containing thymoquinone increases the IGF-1 gene expression level by 1.33 times compared to the control. In addition, it can be seen that Example 1 exhibits a superior IGF-1 gene expression promoting effect, even though the content of resveratrol, which is known to promote IGF-1 gene expression, is less than one-tenth of that of Comparative Example 1 containing resveratrol. From the above, it can be seen that the oral composition of the present invention has a superior IGF-1 gene expression promoting effect, and therefore has an effect of maintaining and / or increasing muscle mass and an effect of preventing and / or improving physical frailty.
[0031] 2. Evaluation of mitochondrial activation ability It has been pointed out that the mechanism of fatigue is a decrease in energy production in mitochondria, and it is believed that oxidative stress caused by excessive production of active oxygen due to overwork, stress, etc. inhibits the mitochondrial electron transport system, reduces energy production, and reduces cellular and neurological functions, resulting in a fatigued state (reduced performance, feeling of fatigue). Therefore, by confirming the mitochondrial activation effect, it is possible to confirm the effect of improving basal metabolism, anti-fatigue effect, and prevention and / or improvement of physical frailty. [Test substance] The following substances were used as test substances. A commercially available powdered extract containing thymoquinone was used. Resveratrol: A commercially available product was used as a positive control.
[0032] [Preparation of test substance] Each test substance was prepared as follows. Each test substance was dissolved in DMSO and diluted with differentiation-inducing medium so that the DMSO concentration was 0.5%. 2% HS (horse serum)-DMEM was used as the differentiation-inducing medium. The contents of the test substances used in the following tests are shown in Table 2.
[0033] [Table 2]
[0034] [Measurement of mitochondrial membrane potential] (1) Mouse myoblast cells (C2C12) were plated on a collagen-coated 96-well black plate at 8.0 × 10 3 The cells were seeded at 200 cells / well and cultured for 24 hours in a 5% CO2 incubator at 37°C. (2) After removing the medium, the cells were washed twice with DMEM, and then 200 μL / well of differentiation-inducing medium (2% HS-DMEM) was added and cultured for 7 days in a 37°C, 5% CO2 incubator (to induce differentiation into myotubes). The medium was replaced every 2 to 3 days. (3) After culturing for 7 days, the medium was removed and differentiation-inducing medium containing the test substance was added at 200 μL / well. (4) After culturing for 1 hour in a 37℃, 5% CO2 incubator, 20μL / well of differentiation-inducing medium containing dexamethasone was added (final dexamethasone concentration: 100μM). Dexamethasone was dissolved in DMSO and diluted with differentiation-inducing medium so that the DMSO concentration was 0.5%. (7) After culturing for 24 hours in a 37°C, 5% CO2 incubator, the cells were washed three times with DMEM, 10 μM Rhodamine 123 was added at 50 μL / well, and stained for 30 minutes in a 37°C, 5% CO2 incubator. (8) Wash twice with PBS. (9) PBS was added, and the fluorescence intensity was measured at an excitation wavelength of 507 nm and a fluorescence wavelength of 529 nm. The relative values were calculated using the control without the addition of the test substance as the standard (100). The results are shown in Figure 2.
[0035] 2, it can be seen that Example 2 containing thymoquinone has a 12.2% increase in mitochondrial activation activity compared to the control. In addition, it can be seen that Example 2 exhibits a superior mitochondrial activation activity compared to Comparative Example 2 containing resveratrol, which is known to have a mitochondrial activation activity, even though the content is less than one-tenth of that of Comparative Example 2. From the above, it can be seen that the oral composition of the present invention has a superior mitochondrial activation activity, and therefore has a basal metabolism improving effect, an anti-fatigue effect, and an effect of preventing and / or improving physical frailty.
[0036] 3. Evaluation of mouse grip strength [Test substance] The following substances were used as test substances. A commercially available powdered extract containing thymoquinone was used.
[0037] [Preparation of test substance] Each test substance was prepared as follows. Each test substance was suspended in 0.1% sodium tripolyphosphate solution to prepare a test substance concentration of 8.34 mg / mL as thymoquinone. The doses of the test substances used in the following tests are shown in Table 3.
[0038] [Table 3]
[0039] [Grip strength measurement] (1) Laboratory animals and breeding methods Seven-week-old male C57BL / 6J mice were acclimated and then divided into groups based on their body weight at 8 weeks of age. From the acclimation period until the end of the study, the mice were allowed to freely consume MF solid feed and water. (2) Method of administering the test substance A suspension of each sample was prepared using 0.1% sodium tripolyphosphate solution, and thymoquinone was administered orally to mice by force once a day for 10 days at a volume of 10 mL / kg. The group administered with only 0.1% sodium tripolyphosphate solution containing no thymoquinone (0 mg / kg) served as the control. In addition, dexamethasone sodium phosphate (20 mg / kg) was intraperitoneally administered to each group once a day for 7 days starting from the 4th day of the start of thymoquinone administration to induce a decrease in body weight (muscle). (3) After administration on the 10th day from the start of the test, the grip strength of the mice was measured using a digital force gauge (manufactured by Imada Co., Ltd.) equipped with a wire mesh for measurement. Specifically, the mice were placed on the measurement mesh, and the mice were made to grab the measurement mesh and pull on their tails to measure the grip strength of their limbs. The results are shown in Figure 3.
[0040] 3, it can be seen that the grip strength of the limbs was increased in the group of Example 3 in which thymoquinone was administered, as compared to the control group. From the above, it can be seen that the oral composition of the present invention has an excellent effect of maintaining and / or improving muscle strength and an effect of preventing and / or improving physical frailty.
[0041] 4. Assessment of Mouse Body Weight [Test substance] The following substances were used as test substances. A commercially available powdered extract containing thymoquinone was used.
[0042] [Preparation of test substance] Each test substance was prepared as follows. Each test substance was suspended in 0.1% sodium tripolyphosphate solution to prepare a test substance concentration of 8.34 mg / mL as thymoquinone. The contents of the test substances used in the following tests are shown in Table 4.
[0043] [Table 4]
[0044] [Weight measurement] (1) Laboratory animals and breeding methods Seven-week-old male C57BL / 6J mice were acclimated and then divided into groups based on their body weight at 8 weeks of age. From the acclimation period until the end of the study, the mice were allowed to freely consume MF solid feed and water. (2) Method of administering the test substance A suspension of each sample was prepared using 0.1% sodium tripolyphosphate solution, and thymoquinone was administered orally by gavage to mice at 10 mL / mL once a day for 10 days. The group administered with only 0.1% sodium tripolyphosphate solution containing no thymoquinone (0 mg / kg) served as a control. In addition, dexamethasone sodium phosphate (20 mg / kg) was intraperitoneally administered to each group once a day for 7 days starting from the 4th day of the start of thymoquinone administration to induce a decrease in body weight (muscle). (4) Body weight was measured every day at a specific time, and the results are shown in Figure 4 as changes in body weight.
[0045] 4, it can be seen that in Example 4, in which thymoquinone was administered, muscle atrophy induced by dexamethasone was suppressed and body weight was maintained compared to the control group. From the above, it can be seen that the oral composition of the present invention has an excellent effect of maintaining body weight and preventing and / or improving physical frailty.
[0046] <Production Examples 1 to 5> Tablets (350 mg) were produced according to the composition shown in Table 1 below. Specifically, the ingredients shown in Table 1 were mixed and directly compressed using a tablet press to produce the tablets. Since the obtained composition contains thymoquinone and / or thymohydroquinone, taking three tablets once or twice a day with water can provide excellent effects of preventing and / or improving physical frailty, maintaining and / or increasing muscle mass, maintaining and / or improving muscle strength, anti-fatigue, maintaining body weight, and improving basal metabolism.
[0047] [Table 5]
[0048] <Production Examples 6 to 9> A soft capsule (content liquid 400 mg) was produced according to the composition shown in Table 2 below. Specifically, the components shown in Table 2 were mixed to produce the content liquid, and the resulting content liquid was wrapped in a gelatin membrane to produce the soft capsule. Since the resulting composition contains thymoquinone and / or thymohydroquinone, taking two capsules with water once or twice a day can provide excellent physical frailty prevention and / or improvement effects, muscle mass maintenance and / or increase effects, muscle strength maintenance and / or improvement effects, anti-fatigue effects, weight maintenance effects, and basal metabolism improvement effects.
[0049] [Table 6]
[0050] <Production Examples 10-12> Granules were produced according to the composition shown in Table 3 below. Specifically, the components shown in Table 3 were mixed and granules were produced using a fluidized bed granulator. The obtained composition contains thymoquinone and / or thymohydroquinone, and therefore, by dissolving 20 g in water and taking it once or twice a day, it is possible to enjoy excellent physical frailty prevention and / or improvement effects, muscle mass maintenance and / or increase effects, muscle strength maintenance and / or improvement effects, anti-fatigue effects, weight maintenance effects, and basal metabolism improvement effects.
[0051] [Table 7]
[0052] <Production Examples 13-15> A lotion was produced according to the composition shown in Table 4 below. Since the obtained composition contains thymoquinone and / or thymohydroquinone, by applying an appropriate amount to the legs, arms, etc. once or twice a day, it is possible to enjoy excellent effects of preventing and / or improving physical frailty, maintaining and / or increasing muscle mass, maintaining and / or improving muscle strength, anti-fatigue effects, maintaining body weight, and improving basal metabolism.
[0053] [Table 8]
[0054] <Production Examples 16-18> An emulsion was produced according to the composition shown in Table 5. Since the obtained composition contains thymoquinone and / or thymohydroquinone, by applying an appropriate amount to the legs, arms, etc. once or twice a day, it is possible to enjoy excellent effects of preventing and / or improving physical frailty, maintaining and / or increasing muscle mass, maintaining and / or improving muscle strength, anti-fatigue effects, maintaining body weight, and improving basal metabolism.
[0055] [Table 9]
[0056] <Examples 19-21> A cream was produced according to the composition shown in Table 6 below. Since the obtained composition contains thymoquinone and / or thymohydroquinone, by applying an appropriate amount to the legs, arms, etc. once or twice a day, it is possible to enjoy excellent effects of preventing and / or improving physical frailty, maintaining and / or increasing muscle mass, maintaining and / or improving muscle strength, anti-fatigue effects, maintaining body weight, and improving basal metabolism.
[0057] [Table 10] [Industrial Applicability]
[0058] The composition of the present invention contains thymoquinone and / or thymohydroquinone, and therefore provides a composition that has excellent effects of preventing and / or improving physical frailty, maintaining and / or increasing muscle mass, maintaining and / or improving muscle strength, anti-fatigue effects, maintaining body weight, and improving basal metabolism, and therefore has high industrial applicability.
Claims
1. A composition for preventing and / or improving physical frailty, comprising thymoquinone and / or thymohydroquinone.
2. A composition for maintaining and / or increasing muscle mass, comprising thymoquinone and / or thymohydroquinone.
3. A composition for maintaining and / or improving muscle strength, comprising thymoquinone and / or thymohydroquinone.
4. An anti-fatigue composition comprising thymoquinone and / or thymohydroquinone.
5. A composition for maintaining body weight, comprising thymoquinone and / or thymohydroquinone.
6. A composition for improving basal metabolism, comprising thymoquinone and / or thymohydroquinone.
Citation Information
Patent Citations
Frailty prevention agents, as well as medicines, foods and beverages for frailty prevention
JP7236712B1
